I agree anyone lightening their position to try and time re-entry is playing Russian roulette with their cost basis this close to a completed Phase 3 trial and international EUA submissions because many investors, new and long, are still scooping up shares, knowing all these prices are bargains in the near-future and they don't fret over pennies like the nervous nellies do.

I disagree that the call was unnecessary, at least from the perspective of gathering insight from the management on their progress and timelines, rather than just waiting for trial data and Nasdaq uplisting. The calls seem to always have a short-lived dip the share price, and that seems to bother a lot of people who check their portfolio everyday like obese person who need to weigh themselves everyday to see if they've lost more weight.

At this point, it's just become amusing that informed shareholders care about the stock's reaction to these calls, unless they are looking to buy more and/or take some small gains in the single-digits. Shorts love this stock namely because clinical trials take time to produce tangible results, so they have clear windows to short, and many people who invest in biotech are relatively clueless and easily spooked due to its volatility. I've grown to see that all as opportunity to build a long position, and also make some quick cash on the swings.